<--- Back to Details
First PageDocument Content
Yehuda Shoenfeld / Autoimmunity / Autoimmune disease / Betty Diamond / Rheumatology / La Jolla Institute for Allergy and Immunology / Michael D. Lockshin / Medicine / Rheumatologists / Year of birth missing
Date: 2013-09-13 12:26:25
Yehuda Shoenfeld
Autoimmunity
Autoimmune disease
Betty Diamond
Rheumatology
La Jolla Institute for Allergy and Immunology
Michael D. Lockshin
Medicine
Rheumatologists
Year of birth missing

A message from Kellie Martin... AARDA FY

Add to Reading List

Source URL: www.aarda.org

Download Document from Source Website

File Size: 363,55 KB

Share Document on Facebook

Similar Documents

ADVANCES IN RHEUMATOLOGY Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College NOVEMBER/DECEMBER 2014 The rheumatology program at NewYorkPresbyterian Hospital is compris

ADVANCES IN RHEUMATOLOGY Affiliated with Columbia University College of Physicians and Surgeons and Weill Cornell Medical College NOVEMBER/DECEMBER 2014 The rheumatology program at NewYorkPresbyterian Hospital is compris

DocID: 1fzzx - View Document

Presentation of Navigare Patient Flow and Positioning Product Group: Biological Drugs Target Groups: Rheumatologists Dermatologists Gastroenterologists Countries:

Presentation of Navigare Patient Flow and Positioning Product Group: Biological Drugs Target Groups: Rheumatologists Dermatologists Gastroenterologists Countries:

DocID: 1eAsN - View Document

Developed in Partnership with Rheumatologists Raintree Delivers EMR and Practice Management in a Single Software Solution

Developed in Partnership with Rheumatologists Raintree Delivers EMR and Practice Management in a Single Software Solution

DocID: 1d2Up - View Document

Important Safety Information for Rheumatologists About Risks in Patients Receiving ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administrati

Important Safety Information for Rheumatologists About Risks in Patients Receiving ACTEMRA® ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist that has been approved by the Food and Drug Administrati

DocID: 1bTad - View Document

542  CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials

542 CONCISE REPORT Formative research in clinical trial development: attitudes of patients with arthritis in enhancing prevention trials

DocID: 1anTs - View Document